-
公开(公告)号：WO2017083582A1
公开(公告)日：2017-05-18
申请号：PCT/US2016/061427
申请日：2016-11-10
Applicant: SIAMAB THERAPEUTICS, INC.
Inventor： EAVARONE, David A. , PRENDERGAST, Jillian M. , BEHRENS, Jeffrey , LUGOVSKOY, Alexey Alexandrovich , DRANSFIELD, Daniel T.
IPC: A61K39/395 , C07K16/00 , C07K16/30 , G01N33/574
CPC classification number: A61K47/6803 , A61K47/6851 , A61K2039/505 , C07K16/3092 , C07K2317/24 , C07K2317/33 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.
Abstract translation: 本发明提供了聚糖相互作用抗体以及用于产生可用于治疗和预防人类疾病（包括癌症）的聚糖相互作用抗体的方法。 此类与聚糖相互作用的抗体包括人源化抗体，其衍生物和片段以及相关组合物和试剂盒。 包括使用聚糖相互作用抗体进行治疗和诊断的方法。
-
公开(公告)号：WO2016201240A1
公开(公告)日：2016-12-15
申请号：PCT/US2016/036907
申请日：2016-06-10
Inventor： EAVARONE, David A. , DESANDER, Julie , BEHRENS, Jeffrey , RUEDA, Bo R. , FOSTER, Rosemary , STARBUCK, Kristen D.
IPC: A61K39/00 , A61K39/395 , A61K47/02 , A61K47/12
CPC classification number: C07K16/3069 , A61K39/395 , A61K47/6803 , A61K47/6851 , A61K47/6869 , A61K2039/505 , C07K16/3076 , C07K2317/52 , C07K2317/56 , C07K2317/73
Abstract: The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.
Abstract translation: 本发明提供了通过从培养物中分离癌干细胞，使其与抗被测试的抗-STN抗体接触并测量所得到的细胞存活力来测试抗STN抗体的靶向癌干细胞的能力的方法。
-
公开(公告)号：WO2015054600A2
公开(公告)日：2015-04-16
申请号：PCT/US2014/060079
申请日：2014-10-10
Applicant: SIAMAB THERAPEUTICS, INC.
Inventor： DA SILVA, Ana Paula Galvao , ZHANG, Mai , GHADERI, Darius , PURNAJO, Intan , HERMANN, Julie , BEHRENS, Jeffrey
IPC: C12P21/02
CPC classification number: C07K16/44 , A61K9/0019 , A61K47/6835 , A61K2039/505 , A61K2039/545 , C07K2317/24 , C07K2317/732 , C07K2317/92
Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.
Abstract translation: 本发明提供了聚糖相互作用的抗体和用于生产可用于治疗和预防人类疾病（包括癌症）的聚糖相互作用的抗体的方法。 这样的聚糖相互作用抗体包括单克隆抗体，其衍生物和片段，以及包含它们的组合物和试剂盒。
-
公开(公告)号：WO2017132486A1
公开(公告)日：2017-08-03
申请号：PCT/US2017/015301
申请日：2017-01-27
Inventor： EAVARONE, David A. , BEHRENS, Jeffrey , PRENDERGAST, Jillian M. , RUEDA, Bo R. , FOSTER, Rosemary , STARBUCK, Kristen D.
CPC classification number: A61K9/0019 , A61K31/00 , A61K33/24 , A61K38/00 , A61K39/39558 , A61K47/6803 , A61K47/6851 , A61K47/6869 , A61K2039/505 , A61P35/00 , C07K16/44 , C07K2317/73 , G01N33/574 , A61K2300/00
Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.
Abstract translation: 提供了用于治疗卵巢癌的组合物和方法。 方法包括与化学治疗剂和抗STn抗体的联合治疗。 化疗耐药的卵巢癌细胞可能会减少。 化疗耐药的卵巢癌细胞可能包括癌症干细胞。
-
Patent Agency Ranking
公开(公告)号：WO2016057916A1
公开(公告)日：2016-04-14
申请号：PCT/US2015/054936
申请日：2015-10-09
Applicant: SIAMAB THERAPEUTICS, INC.
Inventor： DA SILVA, Ana Paula Galvao , DESANDER, Julie , BEHRENS, Jeffrey , GHADERI, Darius , ZHANG, Mai , MEETZE, Kristan
IPC: C07K16/00
CPC classification number: C07K16/44 , A61K39/39558 , A61K2039/505 , C07K16/3015 , C07K16/3046 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/77
Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. In some embodiments, the present invention provides an antibody having a heavy chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 63 and having a light chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 64.
Abstract translation: 本发明提供了聚糖相互作用的抗体和用于生产可用于治疗和预防人类疾病（包括癌症）的聚糖相互作用的抗体的方法。 这样的聚糖相互作用抗体包括单克隆抗体，衍生物及其片段，以及包含它们的组合物和试剂盒。 在一些实施方案中，本发明提供了具有重链的抗体，所述重链具有与SEQ ID NO：63具有至少95％序列同一性的氨基酸序列，并具有与SEQ ID NO：63具有至少95％序列同一性的氨基酸序列的轻链 SEQ ID NO：64。
-
公开(公告)号：WO2014194053A3
公开(公告)日：2014-12-04
申请号：PCT/US2014/039963
申请日：2014-05-29
Applicant: SIAMAB THERAPEUTICS, INC.
Inventor： ZHANG, Mai , GHADERI, Darius , BEHRENS, Jeffrey , HERMANN, Julie
IPC: A23L1/30
Abstract: Embodiments of the present invention provide compositions and methods for the modulation of sialic acid levels. In some embodiments, compositions disclosed herein comprise nutraceuticals as functional agents.
-
公开(公告)号：WO2018094143A1
公开(公告)日：2018-05-24
申请号：PCT/US2017/062155
申请日：2017-11-17
Applicant: SIAMAB THERAPEUTICS, INC.
Abstract: The present disclosure provides antibodies with T cell-interacting regions and/or glycan-interacting regions. Bispecific antibodies capable of recruiting T cells to cancer cells are also provided, including bispecific antibodies capable of recruiting T cells to cancer cells expressing sialyl Tn (STn). The present disclosure also includes methods for killing cells by targeting them with antibodies having T cell-interacting regions.
-
公开(公告)号：WO2016077526A1
公开(公告)日：2016-05-19
申请号：PCT/US2015/060287
申请日：2015-11-12
Applicant: SIAMAB THERAPEUTICS, INC.
Inventor： DA SILVA, Ana Paula Galvao , GHADERI, Darius , ZHANG, Mai , PURNAJO, Intan , MEETZE, Kristan , DESANDER, Julie , BEHRENS, Jeffrey , EAVARONE, David A. , PRENDERGAST, Jillian M. , LUGOVSKOY, Alexey Alexandrovich
IPC: A61K39/395 , A61K39/00 , C07K16/00
CPC classification number: G01N33/57492 , A61K47/48438 , A61K47/48569 , C07K16/005 , C07K16/3076 , C07K16/44 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.
Abstract translation: 本发明提供了聚糖相互作用的抗体和用于生产可用于治疗和预防人类疾病（包括癌症）的聚糖相互作用的抗体的方法。 这样的聚糖相互作用抗体包括单克隆抗体，衍生物及其片段，以及包含它们的组合物和试剂盒。 还提供了使用聚糖相互作用抗体靶向细胞并治疗疾病的方法。
-
公开(公告)号：WO2016057890A1
公开(公告)日：2016-04-14
申请号：PCT/US2015/054877
申请日：2015-10-09
Applicant: SIAMAB THERAPEUTICS, INC.
Inventor： DA SILVA, Ana Paula Galvao , ZHANG, Mai , GHADERI, Darius , DESANDER, Julie , BEHRENS, Jeffrey , PRENDERGAST, Jillian
IPC: C40B40/12
CPC classification number: C07H15/04 , C40B40/12 , G01N33/57484 , G01N33/6854 , G01N2400/12 , G01N2400/38
Abstract: The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.
Abstract translation: 本发明提供了用于分析聚糖和抗聚糖抗体的方法和工具，例如聚糖阵列。 本发明的实施方案可用于检测蛋白质，抗体，疾病和/或病原体。 在其它实施方案中，本发明的方法用于开发或优化阵列和抗体。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.019 seconds)
